ARAF and astrocytoma (excluding glioblastoma): Thus, for tumors that are driven by BRAF dimers, such as low-grade astrocytomas with KIAA2549:BRAF, sparing of ARAF may provide an improved therapeutic window relative to pan-RAF inhibition.